Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | PKM | P14618 | 1/20 | 0.46 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.41 |
| ▸ | IDO1 | P14902 | 2/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | CTSC | P53634 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2467478 | 0.77 | MEN1 (0.53) | MEN1KMT2APKMCTDSP1CYP2C19 | |
| SCHEMBL10453959 | 0.74 | MEN1 (0.53) | MEN1KMT2APKMCTDSP1SLC6A3 | |
| SCHEMBL3966889 | 0.74 | MEN1 (0.53) | MEN1KMT2APKMCTDSP1SLC6A3 | |
| SCHEMBL2465315 | 0.72 | PKM (0.62) | NPC1MEN1KMT2APKMCTDSP1 | |
| SCHEMBL3121803 | 0.72 | MEN1 (0.54) | MEN1KMT2APKMCTDSP1SLC6A3 | |
| SCHEMBL1005727 | 0.72 | MEN1 (0.54) | MEN1KMT2APKMCTDSP1IDO1 | |
| SCHEMBL2085660 | 0.72 | MEN1 (0.58) | MEN1KMT2APKMCTDSP1IDO1 | |
| SCHEMBL966816 | 0.72 | MEN1 (0.58) | MEN1KMT2APKMCTDSP1IDO1 | |
| SCHEMBL8921364 | 0.72 | MEN1 (0.54) | MEN1KMT2APKMCTDSP1SLC6A3 | |
| SCHEMBL5508578 | 0.71 | MEN1 (0.54) | MEN1KMT2APKMCTDSP1IDO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110224209-A1 | 4,4-DISUBSTITUTED PIPERIDINE DERIVATIVES USEFUL AS INHIBITORS OF DIPEPTIDYL PEPTIDASE-1 (DPP-1) | JANSSEN PHARMACEUTICA N.V. (BE) | 2011-09-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110224209-A1 | 4,4-DISUBSTITUTED PIPERIDINE DERIVATIVES USEFUL AS INHIBITORS OF DIPEPTIDYL PEPTIDASE-1 (DPP-1) | DPP4, DPP3, DPP7 | NPC1 216/4885RAB9A 3028/4885SMN1; SMN2 2286/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.